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provides beneﬁ ts at other fracture sites as shown in the postmenopausal pivotal trial 
FREEDOM, the ICER reduces to c19,726. a probabilistic SA showed that denosumab 
was a cost-effective option for a willingness to pay >c60,000. CONCLUSIONS: 
Denosumab prevents vertebral fractures in patients with PrCa receiving ADT and is 
cost-effective versus no treatment. Vertebral fractures signiﬁ cantly reduce quality of 
life and since there is no other licensed treatment in Sweden, denosumab represents 
an important option in PrCa at commonly accepted CE thresholds in Sweden.
PCN84
COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF 
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT 
ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE 
PHASE 2 STUDY (GFPC 0504)
Chouaid C1, Le caer H2, Crequit J3, Monnet I4, Chouabe S5, Locher C6, Paillotin D7, 
Auliac JB8, Thomas P9, Vergnenegre A10
1Hôpital St Antoine, Paris, France; 2Hôpital de draguignan, Draguignan, France; 3Centre 
Hospitalier de Beauvais, Beauvais, France; 4Centre Intercommunal de Creteil, Creteil, France; 
5Centre hospitalier de Charleville Meziere, Charleville Mézières, France; 6Hôpital Saint Faron, 
Meaux, France; 7CHU de Rouen, Rouen, France; 8Service De Pneumologie, mantes la jolie, 
France; 9Centre Hospitalier, GAP, France; 10Hôpital du Cluzeau Service de Pathologie 
Respiratoire, Limoges, France
OBJECTIVES: Median age of newly diagnosed non-small cell lung cance (NSCLC) is 
70 years (with 1/3 older than 75 years) and elderly are more vulnerable to chemo-
therapy. In this population, weekly gemcitabine and docetaxel or erlotinib are both 
active in advanced NSCLC treatment. The GFPC0504 randomized prospective phase 
2 study assess in ﬁ t elderly patients with advanced NSCLC, efﬁ cacy of weekly chemo-
therapy followed by erlotinib if progression (Arm A) versus erlotinib followed by 
chemotherapy if progression (arm B). The main objective of this study was time before 
second progression, secondary objective was overall survival. The objective of this 
study is to assess the cost-effectiveness of erlotinib in ﬁ rst-line treatment of NSCLC 
in ﬁ t elderly patients. METHODS: Outcomes (PFS and overall survival) and direct 
medical costs until second progression (from the third-party payer perspective) were 
prospectively collected. Costs after second progression and health utilities (based on 
disease states and grade 3–4 toxicities) were derived from the literature. RESULTS: 
For respectively 48 and 51 patients randomized respectively in arm a and B, PFS were 
6.4 and 5.2 months, overall survival were 9.2 and 7.9 months; mean Qualy and mean 
direct costs (euros value 2010) were respectively c0.434 ± c0.394 and c26,297 ± 
c25,297 and c0.471 ± c0.451 and c25,948 ± c18,206. Acceptability curve will be 
presented at the meeting. CONCLUSIONS: In this population of ﬁ t ederly patients, 
erlotinb in ﬁ rst line, followed by chemotherapy if progression appears as dominant 
compare to chemotherapy followed by erlotinib if progression.
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OBJECTIVES: Sorafenib and sunitinib are approved for patients with advanced or 
metastatic renal cell carcinoma after INF-a or IL-2 therapy failure or intolerance, with 
PS 0-1 and without CNS metastasis in deﬁ ned cancer centers in the Czech Republic; 
sunitinib is reimbursed for ﬁ rst-line therapy in mRCC patients of good or intermediate 
risk. METHODS: We assessed the cost of sunitinib and sorafenib in patients treated 
in comprehensive cancer center and prepared cost-effectiveness analysis (CEA) to 
compare our data to CEA submitted by manufacturers to Czech authority (SUKL = 
State Institute for Drug Control) in reimbursement proceedings between 2008 and 
2010. (1c = 26CZK). RESULTS: CEA of sunitinib submitted to SUKL was based on 
cost of pharmacotherapy and clinical data of Motzer et al. study (NEJM 2007; time 
to PD: sunitinib 11 months, INF-a 5 months; duration of PD to death 6 months). Cost 
per progression-free year (PFY) was 324144CZK/12467c in manufacturer’s analysis, 
CZK867,946CZK/c33,383 in SUKL analysis (after INF-a cost reduction and costs 
after PD removal) and CZK2,304,914/c88,651 in our analysis (cost and effects of 
sunitinib based on our results; INF-a data were assumed identically). CEA of sorafenib 
was performed for patients after cytokine intolerance or failure (Escudier et al.; NEJM 
2007) in comparison with sunitinib (70% pts) or BSC (30% pts). The cost per PFY 
was CZK965,726/c37,143 in manufacturer’s analysis. Although sorafenib was 
cheaper alternative according to our results, time to progression was shortened by 18 
days (ICER CZK516,820/c1,9878 per PFY). CONCLUSIONS: The cost per PFY in 
sunitinib was seven times lower in manufacturer’s analysis than in CEA based on real 
data from cancer center. We assume that this was mainly caused by shorter time of 
pharmacotherapy in original study (6 vs. 11 months in our data). CEA of sorafenib 
demonstrated lower costs and effects in our analysis, because the signiﬁ cance of 
comparator (70% pts sunitinib) was underestimated in manufacturer’s analysis.
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OBJECTIVES: The aim of a sympathetic blockade is to improve the analgesic 
response, diminish the opioid consumption, reduce the adverse effects from opioides, 
and get efﬁ ciency of costs related to treatment. We analyzed the cost-effectiveness of 
Splanchnic Nerves Blockade (SNB) versus drug therapy in patients with cancer and 
visceral pain at the upper abdomen. METHODS: A cost-effectiveness analysis was 
conducted within a retrospective, follow-up study in patients >18 years with cancer 
and visceral pain. Using medical records, we assessed patients that underwent a SNB 
between March 2005 and December 2009. We evaluated the visual analog pain scale 
(VAS), Karnofsky performance scale (KPS), and medical direct costs. The measures 
were evaluated before and after (1, 2, 3, 6, 9, and 12 months) the procedure. Cost 
methodology was calculated trough cost of illness and microcosting technique, to get 
the incremental cost-effectiveness ratio (ICER). RESULTS: Sixty-ﬁ ve patients were 
treated with SNB and 19 with drug treatment-WHO analgesic ladder steps (mean age 
52.7 ± 12.9 and 54 ± 12.9, respectively). Basal characteristics were not different 
between them. VAS scores diminished in both arms, but at repeated measures ANOVA 
patients on SNB had better pain control (P < 0.05) and higher KPS (P < 0.05). The 
mean cost per patient in 1-year follow-up for the drug treatment group was $7512 
MXP (CI 95% $1587–$13,436 MXP) and $5433 (CI 95% $5114–$5752) for SNB. 
The effectiveness measure was 80% for SNB versus 20% for the drug treatment group, 
respectively. The ICER obtained was negative (−$3526 MXP, IC 95% −5860 to 
−1191), favoring the SNB as a cost-saving alternative. CONCLUSIONS: SNB showed 
to be less costly and more effective than drug treatment alone. However, when a sensi-
tive analysis (bootstrap methodology) was conducted, the sample size was not power-
ful enough for a precise CE estimate.
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OBJECTIVES: Pharmacoeconomic analysis of direct medical costs of mCRC therapy 
using XELOX/FOLFOX4, XELOX + BV/FOLFOX4 + BV. METHODS: Costs of 
diagnosis, medical services, and hospitalization were based on the price list for diag-
nostic and therapeutic procedures of Cancer Research Center n.a. N.N.Blokhin 
RAMS. The medical services patient should receive during the treatment and the 
frequency of their appointments were taken from the standards of medical care for 
patients with colon and rectum cancer. Cost analysis of anticancer drugs (16 courses 
of XELOX/XELOX + BV, 24 courses of FOLFOX4/FOLFOX4 + BV) and related 
drugs were based on the information about maximum selling import prices, registered, 
and entered into the State Register of prices of vitally essential drugs. The cost of other 
drugs was based on a database of retail prices for drugs in pharmacies, which was 
subsequently reduced by trade discount. RESULTS: In was calculated that the cost of 
diagnosis was 16,757 rubles and the medical services—379,815 rubles. The mCRC 
therapy as a ﬁ rst line by XELOX was 1,172,731 rubles and by XELOX + 
BV—2,526,110 rubles; by FOLFOX4—1,487,627 rubles and by FOLFOX4 + 
BV—2,843,558 rubles. The cost saving in applying the regime XELOX compared to 
FOLFOX4 regime amounted to 314,896 rubles. In applying the regime of XELOX in 
combination with BV in comparison with the regime of FOLFOX4 in combination 
with BV amounted to 317,448 rubles. Sensitivity analysis showed that the decrease 
and increase of the cost of capecitabine and bevacizumab in 20% for XELOX/XELOX 
+ BV does not exceed the cost of regimes FOLFOX/FOLFOX4 + BV. CONCLU-
SIONS: From the pharmacoeconomic point of view, the most optimal is the use of 
XELOX and XELOX + BV regimes because of lower costs for neutropenia treatment, 
associated with an increased risk of infectious complications, as well as with a large 
number of hospitalization days.
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OBJECTIVES: To calculate the incremental cost-effectiveness of docetaxel-adriami-
cine-cyclophosphamide (TAC) against adriamicine- cyclophosphamide-5 ﬂ ourouracil 
(FAC) in treatment of breast cancer in south of Iran. METHODS: A double blind 
study was applied on a cohort of 100 patients suffering from breast cancer with node-
positive in the radiotherapy center of Namazi Hospital, Shiraz, Iran. The European 
organization for research and treatment of cancer questionnaire (EORTC QLQ-C30) 
was used for the measuring of quality of life at the ﬁ rst and last session of chemo-
therapy cycle. Third-party payer perspective was applied for costing side of evaluation. 
At last, two-way sensitivity analysis was used for ensuring the robustness of the results. 
